Business
Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
KINECT®-HD2 Is the First Prospective Clinical Trial to Include Patients Taking Antipsychotic Medication in a Study Evaluating a Vesicular Monoamine
About this update from Neurocrine Biosciences, Inc.
[{"type":"text","content":"KINECT®-HD2 Is the First Prospective Clinical Trial to Include Patients Taking Antipsychotic Medication in a Study Evaluating a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor for the Treatment of Huntington's Disease Chorea Findings Presented at the 2024 MDS International Congress of Parkinson's Disease and Movement Disorders®SAN DIEGO, Sept. 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT®-HD2 study of INGREZZA® (valbenazine) capsules for the long-term treatment of adults with chorea associated with Huntington's disease. Robust and sustained improvements in chorea associated with Huntington's disease were observed through Week 104 in patients, irrespective of concomitant antipsychotic therapy use. These results (Poster #1465) will be presented on September 30 during the 2024 MDS International Congress of Parkinson's Disease and Movement Disorders® in Philadelphia.\n\n \n \n \n \n \n \n\n \n\"The data from this study reinforce the long-term clinical safety of INGREZZA observed to date, showing sustained improvement in chorea regardless of antipsychotic use during the study,\" said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences. \"This is an important finding given that approximately a third of patients living with Huntington's disease chorea are prescribed antipsychotic medications for neuropsychiatric symptoms without receiving treatment for the chorea that may significantly disrupt daily life.\"\nThe effect of INGREZZA on chorea over time was assessed using mean changes from baseline in the Unified Huntington's Disease Rating Scale Total Maximal Chorea (TMC) score and response status (\"much improved\" or \"very much improved\") for Clinical Global Impression of Change and Patient Global Impression of Change.\nData from this interim analysis of KINECT-HD2 suggest robust and sustained improvements in Huntington's disease (HD) chorea with INGREZZA treatment:\nINGREZZA improved HD chorea as early as Week 2 (TMC change from baseline: -3.4) at the starting dose of 40 mg and at Week 4 (-4.6) with doses up to 60 mg. Efficacy was sustained from Week 8 (-5.7) to Week 104 (-5.2) at the maintenance dose of up to 80 mg.These improvements were consistent regardless of presence or absence of concomitant antipsychotic treatment....